CG Oncology Inc. (CGON) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, CG Oncology Inc. (NASDAQ: CGON) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $61.96 (-4.20% 1D, market cap $5.49B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, CGON ranks #418 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGON carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.8%. By comparison, SRRK (Scholar Rock Holding Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $5.23B) and IMVT (Immunovant Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $5.87B). Among the 5-stock peer group, CGON leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).
Per CGON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001991792), CG Oncology Inc. generated $534.2M in revenue (+66.4% YoY), -$161.0M in net income, and -$132.5M in free cash flow against $791.6M in total assets and $3.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
20D Institutional Volume Accumulation (±7.8% realized swing band)
Macro rate sensitivity & RSI-14 (41.5) create a -15 pt regime headwind
While CGON currently carries a cautious 42/100 (D-) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($68.20) and Max Pain ($65.06) forces dealer call-delta covering toward $85.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
CG Oncology Inc. (CGON) dropped -4.20% to $61.96, trading at 58% of its 52-week range ($35.8 – $80.97). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Kalkine India report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than
Genmab has gone from specialist biotech to front-page story after three cancer drugs cleared key Phase 3 hurdles and the stock price doubled in just three months. That kind of sudden spotlight often leaves some investors
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +66.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CGON today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CGON. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, CG Oncology Inc. (CGON) ranks #418 by composite RQD confidence (42/100, grade D-) and #149 by equity capitalization ($5.49B). Within this direct 5-issuer industry benchmark cohort, CGON leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and — gross margin. KOD currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with CGON at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CGON
ACTIVE
CG Oncology Inc. | D- | 42/100 | — | — | -20.8% | -4.20% | $5.49B | Benchmark Subject |
| SRRK Scholar Rock Holding Corporation | D- | 41/100 | — | — | -35.0% | -2.25% | $5.23B | /srrk-vs-cgon → |
| IMVT Immunovant Inc. | D- | 37/100 | — | — | -35.0% | -2.60% | $5.87B | /imvt-vs-cgon → |
| KOD Kodiak Sciences Inc | D+ | 54/100 | — | — | -35.0% | -1.57% | $6.14B | /kod-vs-cgon → |
| CRSP CRISPR Therapeutics AG | D- | 35/100 | — | — | -30.6% | -2.78% | $4.83B | /crsp-vs-cgon → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), CG Oncology Inc. (CGON) reported GAAP revenue of $534.2M (+66.4% vs. FY2024 revenue of $321.1M , and +244.1% cumulative change since FY2023) , GAAP net income of -$161.0M, operating cash flow of -$132.3M, and free cash flow of -$132.5M (-67.8% YoY). On the balance sheet, CGON closed FY2025 with $791.6M in total assets against $3.0M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $534.2M | -$161.0M | -$132.3M | -$132.5M | $791.6M | $3.0M |
| FY2024 (FY) | 2024-12-31 | $321.1M | -$88.0M | -$78.7M | -$78.9M | $754.8M | $0 |
| FY2023 (FY) | 2023-12-31 | $155.3M | -$48.6M | -$45.7M | -$45.7M | $3.09B | $724.1M |
As of 2026-11-03, CG Oncology Inc. (NASDAQ: CGON) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $61.96 (-4.20% 1D, market cap $5.49B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, CGON ranks #418 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGON carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.8%. By comparison, SRRK (Scholar Rock Holding Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $5.23B) and IMVT (Immunovant Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $5.87B). Among the 5-stock peer group, CGON leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).
Per CGON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001991792), CG Oncology Inc. generated $534.2M in revenue (+66.4% YoY), -$161.0M in net income, and -$132.5M in free cash flow against $791.6M in total assets and $3.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CGON last traded at $61.96 (-4.20% on volume of 1,279,560 shares), positioning the stock -9.15% below its 50-day simple moving average ($68.20) and -6.22% below its 200-day simple moving average ($66.07). Across its 52-week range of $35.80 to $80.97, CGON sits at the 57.9% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($57.13 to $66.79).
CG Oncology Inc. (CGON) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $61.96 (-4.20% 1D, market capitalization $5.49B).
CG Oncology Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. Reported revenue is — in each of the three listed fiscal years, so the source does not show a revenue-generating operating base.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CG Oncology Inc. (CGON) reported $534.2M in annual revenue (up from $321.1M in FY2024, +66.4% YoY) and -$161.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($155.3M revenue, -$48.6M net income) through FY2025, CGON scaled operating cash flow to -$132.3M and free cash flow to -$132.5M, backed by $791.6M in total assets against $3.0M in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), CGON carries a macro regime beta of 1.07 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for CG Oncology Inc. (CGON) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
Kalkine India report covering CG Oncology Inc. (CGON) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating CG Oncology Inc. (CGON). The forensic balance sheet pillar scores 14/20 with an Altman Z-Score of 26, the strongest pillar in the rating.. With an RQD score of 42/100 (D-) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $69.85.
Both sides have a point here — CGON's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
I respect the product at CG Oncology Inc., but the stock at $64.68 is a different story. ROIC of -20.8% and FCF of -$132.5M in FY 2025 show the cash engine is consuming capital, with cash down from $257.1M to $32.5M.. FCF yield is -2.35% and RQD sits at 42/100 (D-) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: